EA202191764A1 - Замещенные оксопиридиновые производные - Google Patents

Замещенные оксопиридиновые производные

Info

Publication number
EA202191764A1
EA202191764A1 EA202191764A EA202191764A EA202191764A1 EA 202191764 A1 EA202191764 A1 EA 202191764A1 EA 202191764 A EA202191764 A EA 202191764A EA 202191764 A EA202191764 A EA 202191764A EA 202191764 A1 EA202191764 A1 EA 202191764A1
Authority
EA
Eurasian Patent Office
Prior art keywords
oxopyridine derivatives
substituted oxopyridine
substituted
derivatives
preparation
Prior art date
Application number
EA202191764A
Other languages
English (en)
Russian (ru)
Inventor
Зузанне Рёхриг
Зебастиан Эссиг
Паскаль Эллерброкк
Зоня Анлауф
Томас Неубауэр
Александер Хиллиш
Катарина Майер
Штефан Найтмайер
Адриан Терстееген
Мартина Шефер
Ян Штампфусс
Дитер Ланг
Хонгпинг Ванг
Цзэнцян Цзоу
Сянхай Мэн
Керстен Маттиас Герике
Original Assignee
Байер Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Акциенгезельшафт filed Critical Байер Акциенгезельшафт
Publication of EA202191764A1 publication Critical patent/EA202191764A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EA202191764A 2018-12-21 2019-12-18 Замещенные оксопиридиновые производные EA202191764A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018122825 2018-12-21
PCT/EP2019/085983 WO2020127504A1 (en) 2018-12-21 2019-12-18 Substituted oxopyridine derivatives

Publications (1)

Publication Number Publication Date
EA202191764A1 true EA202191764A1 (ru) 2021-10-22

Family

ID=69143542

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191764A EA202191764A1 (ru) 2018-12-21 2019-12-18 Замещенные оксопиридиновые производные

Country Status (22)

Country Link
EP (1) EP3898633A1 (es)
JP (1) JP2022514303A (es)
KR (1) KR20210106504A (es)
CN (1) CN113474348A (es)
AR (1) AR117435A1 (es)
AU (1) AU2019407909B2 (es)
BR (1) BR112021009435A2 (es)
CA (1) CA3124220A1 (es)
CL (1) CL2021001613A1 (es)
CO (1) CO2021007908A2 (es)
CR (1) CR20210342A (es)
DO (1) DOP2021000128A (es)
EA (1) EA202191764A1 (es)
EC (1) ECSP21043895A (es)
IL (1) IL283990A (es)
JO (1) JOP20210161A1 (es)
MA (1) MA54521A (es)
MX (1) MX2021007508A (es)
PE (1) PE20211790A1 (es)
SG (1) SG11202104384PA (es)
TW (1) TW202039510A (es)
WO (1) WO2020127504A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3765452T (pt) * 2018-03-15 2022-06-23 Bayer Pharma AG Processo preparativo de dois derivados de 4-{[(2s)-2-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-5-metoxi-2-oxopiridin-1(2h)-il}butanoil]amino}-2-fluorbenzamida
CN114105881B (zh) 2020-08-31 2024-01-26 沈阳海诺威医药科技有限公司 血小板聚集抑制剂及其制备方法和用途
WO2022189280A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
JP2024508970A (ja) 2021-03-09 2024-02-28 バイエル・アクチエンゲゼルシヤフト （４ｓ）－２４－クロロ－４－エチル－７３－フルオロ－３５－メトキシ－３２，５－ジオキソ－１４－（トリフルオロメチル）－３２ｈ－６－アザ－３（４，１）－ピリジナ－１（１）－［１，２，３］トリアゾラ－２（１，２），７（１）－ジベンゼナヘプタファン－７４－カルボキサミドを含んでいる医薬剤形
CN117015535A (zh) 2021-03-09 2023-11-07 拜耳公司 (4s)-24-氯-4-乙基-73-氟-35-甲氧基-32,5-二氧代-14-(三氟甲基)-32h-6-氮杂-3(4,1)-吡啶-1(1)-[1,2,3]三唑-2(1,2),7(1)-5二苯庚烷-74-甲酰胺的结晶形式
CN114560754A (zh) * 2022-02-25 2022-05-31 滁州学院 一种烷基醇的制备方法
CN116874469B (zh) * 2023-09-06 2023-11-10 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物、中间体及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
DE102006032824A1 (de) * 2006-07-14 2008-01-17 Bayer Healthcare Ag Substituierte Indazole
EP2091947A2 (en) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Glucokinase activators
WO2014160592A2 (en) 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
TWI633089B (zh) * 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
US9475809B2 (en) 2013-07-23 2016-10-25 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives and use thereof as factor xia/plasma
US9765070B2 (en) 2013-10-30 2017-09-19 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
WO2016046166A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
EP3197880B1 (de) 2014-09-24 2018-10-24 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate mit anti-inflammatorischer und anti-thrombotischer wirkung
ES2694189T3 (es) 2014-09-24 2018-12-18 Bayer Pharma Aktiengesellschaft Derivados de oxopiridina sustituidos
EP3197896B1 (de) 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
WO2016046164A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
US10138236B2 (en) * 2014-09-24 2018-11-27 Bayer Pharma Aktiengesellschaft Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives
EP3271332A1 (de) * 2015-03-19 2018-01-24 Bayer Pharma Aktiengesellschaft Oxopyridin-derivate als faktor xia hemmer zur behandlung von thrombose
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
WO2017037051A1 (de) 2015-09-04 2017-03-09 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate

Also Published As

Publication number Publication date
MX2021007508A (es) 2021-08-05
IL283990A (en) 2021-07-29
AU2019407909B2 (en) 2023-05-25
AR117435A1 (es) 2021-08-04
CR20210342A (es) 2021-08-09
PE20211790A1 (es) 2021-09-09
AU2019407909A1 (en) 2021-05-27
CN113474348A (zh) 2021-10-01
TW202039510A (zh) 2020-11-01
SG11202104384PA (en) 2021-05-28
WO2020127504A1 (en) 2020-06-25
ECSP21043895A (es) 2021-07-30
BR112021009435A2 (pt) 2021-08-17
JOP20210161A1 (ar) 2023-01-30
EP3898633A1 (en) 2021-10-27
CL2021001613A1 (es) 2021-12-03
MA54521A (fr) 2022-03-30
DOP2021000128A (es) 2021-09-30
CA3124220A1 (en) 2020-06-25
KR20210106504A (ko) 2021-08-30
JP2022514303A (ja) 2022-02-10
CO2021007908A2 (es) 2021-07-19

Similar Documents

Publication Publication Date Title
EA202191764A1 (ru) Замещенные оксопиридиновые производные
EA201890111A1 (ru) Замещенные производные оксопиридина
EA202092779A1 (ru) Замещенные дигидропиразолопиразинкарбоксамидные производные
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA202091709A1 (ru) Ингибиторы днк-пк
MY195561A (en) Indole Carboxamide Compounds useful as Kinase Inhibitors
EA201791507A1 (ru) Пирроло- и пиразолопиримидины в качестве ингибиторов убиквитин- специфичной протеазы 7
EA201792354A1 (ru) Композиции обетихолевой кислоты и способы применения
EA201791168A1 (ru) Способы и составы для лечения сосудистых заболеваний глаз
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA202091020A1 (ru) Замещенные имидазопиридинамиды и их применение
EA202091708A1 (ru) Ингибиторы днк-пк
EA201600288A1 (ru) Замещенные фенилаланиновые производные
EA202191122A1 (ru) СЕЛЕКТИВНЫЕ К RGMc ИНГИБИТОРЫ И ИХ ПРИМЕНЕНИЕ
CY1124492T1 (el) 7-υποκατεστημενα 1-αρυλο-ναφθυριδιν-3-καρβοξαμιδια και η χρηση αυτων
EA201792341A1 (ru) Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap)
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA202091655A1 (ru) Композиции и способы лечения нарушений сетчатки
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA202191115A1 (ru) Новые пиридазины
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
EA201992389A1 (ru) Замещенные n-арилэтил-2-аминохинолин-4-карбоксамиды и их применение
EA202092045A1 (ru) Лечение и предупреждение преэклампсии
EA201800565A1 (ru) Композиция для лечения заболеваний уха, содержащая (+)-азасетрон